CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The SCOPE-DMD project aims to develop a personalized therapy for Duchenne Muscular Dystrophy (DMD) using RNA-based technology to restore functional dystrophin protein in targeted patient groups. This innovative approach addresses the clinical complexities of rare diseases and seeks to expedite the pathway to market for…
This project builds on results from the TREAT-NMD and BIO-NMD European projects to develop a personalised-medicinal product through to market for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is an inheritable, childhood rare disease that affects approximately 1 in 3,500 newborn boys.
This rare disease is caused by mutations in the dystrophin gene, resulting in the absence or defect of the dystrophin protein.
As a result, patients suffer from progressive loss of muscle strength, typica…
UNIVERSITY OF NEWCASTLE UPON TYNE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, FRANKFURT AM MAIN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Netherlands, LEIDEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
